Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash.
Orbital Therapeutics is advancing a new generation of RNA medicines designed to reprogram cells in vivo, treating diseases at their source. Its lead RNA immunotherapy preclinical candidate, OTX-201, targets autoimmune disease through B cell depletion to reset the immune system.
In addition to OTX-201, the deal covers Orbital’s proprietary RNA platform, which integrates circular and linear RNA engineering, advanced lipid nanoparticles delivery, and AI-driven design to enable durable, programmable RNA therapies tailored to the distinct biology of a broad spectrum of diseases.
The deal strengthens Bristol Myers Squibb’s cell therapy portfolio. “With the acquisition of Orbital Therapeutics and its next-generation RNA platform, we have an incredible opportunity to make CAR T-cell therapy more efficient and accessible to more patients,” said Lynelle B. Hoch, president, Cell Therapy Organization, Bristol Myers Squibb.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.